Sanofi’s Infilbray (venglustat) has received FDA approval for treating the neurological symptoms of Gaucher disease type 3, positioning it as the first approved therapy in the US specifically targeting brain involvement in this rare lysosomal disorder. The approval underscores continued movement in treatments designed to cross the blood–brain barrier for severe, high-need patient populations. For clinicians and payers, the key operational question will be aligning patient selection and monitoring for a medication whose benefit is focused on neurological manifestations rather than systemic disease alone. Infilbray’s timing also highlights how rare-disease regulatory pathways are being used to address unmet neurologic endpoints when conventional systemic therapies do not adequately treat central nervous system involvement.
Get the Daily Brief